Abstract
Recent reports have demonstrated that male patients with type 2 diabetes (T2D) and hypogonadism receiving combined testosterone replacement therapy (TRT) and sodium-glucose cotransporter-2 inhibitor (SGLT2i) prescription may be at increased risk for erythrocytosis (E). We investigated if the incident E is associated with pathogenic mutation in common HFE genes known to result in hereditary hemochromatosis (HH).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
